This Clinical Pearls session consists of three, 15-minute presentations about unique psych pharmacy patient cases and/or clinical challenges. Each presentation will be recorded, and the three combined sessions are available for 1.0 hour of ACPE credit.
Pseudoephedrine for Clozapine-Induced Nocturnal Enuresis, presented by Jaden Dickinson, PharmD, BCPP
- Review possible mechanism(s) for clozapine-induced nocturnal enuresis.
- Identify non-pharmacological and pharmacological strategies that could be implemented for clozapine-induced nocturnal enuresis.
Summary: Clozapine-induced nocturnal enuresis is an often underreported side effect with no FDA-approved treatment options. Existing literature consists primarily of case reports with limited-quality evidence on both pharmacological and non-pharmacological approaches. This clinical pearl presents another successful case of pseudoephedrine use, utilizing a formulation and dosing schedule not previously published.
Aripiprazole Loading Strategy for Acute Mania, presented by Brianne Mosley, PharmD, BCPS, BCPP
- Summarize evidence for the safety and efficacy of aripiprazole loading for mania.
- Describe strategies to reduce the risk of adverse effects with aripiprazole initiation using a loading dose strategy.
Summary: Aripiprazole monotherapy is recommended as first-line for the treatment of manic episodes of bipolar disorder in adult patients. When compared to alternative pharmacotherapies, aripiprazole is generally considered to have a more favorable side effect profile; however, the medication is underutilized in the inpatient setting. This clinical pearl will review evidence to support a more aggressive initial aripiprazole dosing strategy for acute mania. Clinical pearls to ensure safe implementation of aripiprazole loading strategy will be provided.
Delirious Mania: Navigating Identification, Treatment, and Diagnostic Limbo, presented by Kimberly Ehrhard, PharmD, BCPP
- Identify the distinguishing features of delirious mania, including presentation and symptomatology and controversy of diagnosis.
- Analyze potential treatment modalities for delirious mania, emphasizing the unique challenges and considerations in management.
Summary: Delirious mania (DM) is a rare and severe psychiatric syndrome characterized by a combination of manic, psychotic, catatonic, and delirious symptoms. Despite its distinct clinical presentation, DM lacks formal diagnostic criteria in both the DSM-5 and ICD-10, complicating accurate identification and management. Misdiagnosis or delayed treatment can worsen symptoms and prolong hospitalization, emphasizing the need for greater clinical awareness. Debate continues over whether DM represents a subtype of bipolar disorder, a form of excited catatonia, or a distinct syndrome. This clinical pearl provides a comprehensive overview of DM, focusing on key diagnostic considerations and evidence-based treatment strategies to improve outcomes.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Jaden Dickinson, PharmD, BCPP
Advanced Practice Psychiatric Pharmacist
University of Maryland School of Pharmacy
Baltimore, MD
Dr. Dickinson is an Advanced Practice Psychiatric Pharmacist at the University of Maryland School of Pharmacy. She received her Doctor of Pharmacy degree from Albany College of Pharmacy and Health Sciences. She then completed her PGY1 residency at the VA Maryland Health Care System in Baltimore, Maryland and her PGY2 psychiatric residency at Nova Southeastern University in Fort Lauderdale, Florida. Dr. Dickinson is a board-certified psychiatric pharmacist providing medication management for adults in a forensic state hospital. She is an active member of AAPP and has served on the Student Committee for the past three years.
Brianne Mosley, PharmD, BCPS, BCPP
Psychiatric Clinical Pharmacy Specialist
Medical University of South Carolina
Charleston, SC
Dr. Brianne Mosley is a board-certified psychiatric pharmacist at the Medical University of South Carolina. After earning her Doctor of Pharmacy degree from Ohio Northern University, she completed a first-year pharmacy residency at The Johns Hopkins Hospital and a second-year psychiatric pharmacy residency at M-U-S-C. In her current role she cares for patients in the Psychiatric Emergency Department and on an adult inpatient unit at the M-U-S-C Institute of Psychiatry. Her expertise has allowed her to publish in peer-reviewed psychiatric and neurologic journals and present at local, state, and national conferences.
Kim Ehrhard, PharmD, BCPP
Clinical Pharmacy Specialist – Psychiatry
The University of Kansas Health System
Kansas City, KS
Dr. Ehrhard earned her Doctor of Pharmacy degree from the University of Missouri–Kansas City School of Pharmacy in 2019. She subsequently completed her PGY-1 residency and psychiatric PGY-2 residency at the VA Tennessee Valley Healthcare System in Nashville, Tennessee. She currently serves as a clinical psychiatric pharmacist at the University of Kansas, where she provides care for both inpatient adult and child/adolescent populations. Additionally, Dr. Ehrhard has been an active member of the AAPP Program Committee for the past three years.
Continuing Education Credit and Disclosures
Activity Dates: 04/29/2025 - 04/29/2028
ACPE Contact Hours: 1
ACPE Number: 0284-0000-25-016-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.